Bio-LogX

Bio-LogX (BLX) is a VC-backed translation engine for biological assets. We in-license molecules with functional proof-of-concept data (in-vivo animal or human ex-vivo) and develop them through final candidate to clinical proof of concept – always with the ambition to transform the standard of care. We focus on complex protein-based modalities: antibodies, enzymes, fusions, engagers, degraders, agonists, antagonists, in principle in any therapeutic area. 

Bio-LogX was founded in February 2026 by BioNTech Austria's leadership team.